ClinicalTrials.gg
RecruitingNCT06932874Updated Apr 30, 2025

Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease

A Phase 4 interventional study of Glucophage (Metformin Hydrochloride Tablets) and New sustained-release metformin tablets (Ⅲ) in Atherosclerotic Heart Disease and Type 2 Diabetes, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by China National Center for Cardiovascular Diseases · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases — 26 open to participants now, 27 under way, none of them phase 3. Coronary Artery Disease · China National Center for Cardiovascular Diseases.

Planned enrollment
23rd of 32
356 · median 501
Started
2025
with 9 others
Phase 4
5 of 57
4 open now
Primary completion
2026-12
later than 7 of 26 live
Registered
39th of 57
by date

Among the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases, this one is the 23rd largest by planned enrollment of the 32 interventional ones that give a count, is one of 10 that started in 2025, is one of 5 in phase 4, reaches primary completion later than 7 of the 26 other live ones, and was the 39th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

26 of the 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 26 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Coronary Artery Disease by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

The purpose of this study is1. Compare the differences in the changes of glycated hemoglobin after 24 weeks of treatment between the new metformin sustained-release tablets (Ⅲ) group and the metformin ordinary tablets group.

  1. Compare the differences in the changes of fasting blood glucose, gastrointestinal adverse reactions of the drug and compliance after 24 weeks of treatment between the new metformin sustained-release tablets (Ⅲ) group and the metformin ordinary tablets group.
Read the detailed description

A total of 356 patients with type 2 diabetes mellitus complicated with coronary heart disease were selected. According to the usage of oral hypoglycemic drugs before enrollment, they were divided into the group without using hypoglycemic drugs, the single-drug group (SGLT2i), and the dual-drug group (SGLT2i + DPP4i). Within the same group of subjects, they were randomly divided into the treatment group with the new metformin sustained-release tablets (Ⅲ) (referred to as the experimental group) and the control group with Glucophage (referred to as the control group) at a ratio of 1:1 for 24 weeks of intervention.

Outpatient follow-ups were conducted at baseline, 12 weeks, and 24 weeks, and the differences in glycated hemoglobin, fasting blood glucose changes, gastrointestinal adverse reactions, and compliance were compared between the two groups.

Telephone follow-ups were conducted at 4 weeks, 8 weeks, 16 weeks, and 20 weeks to compare the differences in fingertip blood glucose, gastrointestinal adverse reactions, and compliance.

03

Conditions studied

  • Atherosclerotic Heart Disease
  • Type 2 Diabetes

Keywords

  • Type 2 diabetes
  • coronary atherosclerotic heart disease
  • metformin hydrochloride sustained-release tablets (Ⅲ)
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 30 - 75 years old; : 18.5 - 35 kg/m²
  • T2DM meets the WHO standards of 1999, with ranging from 7% to 9%, and fasting blood glucose ranging from 7 to 10 mmol/L.

    1. Newly diagnosed T2DM patients who only receive dietary control and exercise therapy
    2. T2DM patients who have been diagnosed before, with HbA1c still not reaching the standard after oral hypoglycemic drug treatment for at least 12 weeks, and the oral hypoglycemic drugs include two types: dipeptidyl peptidase-4 inhibitors (DPP-4i) and sodium-glucose cotransporter 2 inhibitors (SGLT2i), and have taken these drugs for at least 4 weeks.
  • Before admission or during this admission, coronary heart disease was diagnosed by coronary angiography, and standard coronary heart disease routine treatment was carried out, including standard antiplatelet therapy, lipid-lowering therapy, and control of ventricular rate. Beta-blockers were uniformly treated with metoprolol sustained-release tablets, and antiplatelet drugs were uniformly treated with aspirin to avoid the influence of coronary heart disease drugs on hypoglycemic effects.

Exclusion criteria

Exclusion Criteria:

  • Within 4 weeks prior to enrollment, used glucagon-like peptide-1 receptor agonists (GLP-1RA) or metformin.
  • Within 4 weeks prior to enrollment, had acute coronary syndrome, severe heart disease other than coronary artery disease, or chronic heart failure ( IV grade).
  • Patients who had failed PCI, planned staged revascularization, or had other types of stent implantation in the past.
  • Patients with acute or chronic pancreatitis, severe neurological diseases, renal dialysis, advanced liver disease, other tumors, organ transplant post-operation, patients with a history of hormone therapy.
  • Special types of diabetes, and endocrine diseases such as hyperthyroidism, hypothyroidism, primary aldosteronism, pheochromocytoma, Cushing's syndrome, congenital adrenal cortical hypofunction, pituitary tumor and hypopituitarism, multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma family or personal history, personal history of non-familial medullary thyroid carcinoma.
  • Pregnant, in the process of pregnancy or lactation during the postpartum period.
  • Within the past 12 weeks, had acute or chronic infectious diseases, fever, anemia, dehydration and electrolyte imbalance, elevated blood lactate level (reaching 2-4 mmol/L).
  • Had lactate acidosis in the past (blood lactate ≥ 5 mmol/L, pH value ≤ 7.35 (arterial blood)).
  • Liver and kidney dysfunction, with and aspartate aminotransferase ≥ 3 times the upper limit, ≤ 45 ml/min/min.
  • Had esophageal reflux, gastric bleeding, peptic ulcer or other severe gastrointestinal diseases within the past 12 weeks.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
356 participants (estimated)

Study arms

  • Active comparator
    Glucophage (Metformin Hydrochloride Tablets)

    Metformin hydrochloride tablets combined with other oral hypoglycemic drugs for 24 weeks treatment.

    Drug: Glucophage (Metformin Hydrochloride Tablets)

  • Experimental
    New type of metformin sustained-release tablets (Ⅲ)

    The experimental group received treatment with New Metformin Sustained-release Tablets (Ⅲ) combined with other oral hypoglycemic drugs for 24 weeks.

    Drug: New sustained-release metformin tablets (Ⅲ)

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Metformin hydrochloride tablets combined with other oral hypoglycemic drugs for 24 weeks treatment.

  • DrugNew sustained-release metformin tablets (Ⅲ)

    The experimental group received treatment with New Metformin Sustained-release Tablets (Ⅲ) combined with other oral hypoglycemic drugs for 24 weeks.

06

What researchers measure

Primary outcomes

  1. Glycated hemoglobin (HbA1c)

    Glycated hemoglobin (HbA1c) at baseline, 12 weeks and 24 weeks through venous blood samples

    Time frame: Baseline, 12 weeks, 24 weeks

Secondary outcomes

  1. Fasting blood glucose

    Baseline, 12 weeks, 24 weeks samples were collected by venous blood draw; while 4 weeks, 8 weeks, 16 weeks and 20 weeks samples were collected by fingertip blood draw.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks

  2. Gastrointestinal adverse reactions

    Evaluate using the "Metformin Adverse Reaction Assessment Form",The scale consists of six items related to dyspepsia symptoms. Each item has a minimum score of 0, indicating no symptoms, and a maximum score of 3, representing symptoms that affect daily life. The higher the score, the more obvious the symptoms are and the worse the outcome.

    Time frame: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, 24 weeks

  3. Medication Adherence

    Medication adherence is evaluated by actual dosage, required dosage and medication treatment rate. Medication treatment rate: assesses the continuous treatment rate of metformin in both groups, the rate of continuous treatment at different dosages, the dropout rate. Continuous treatment rate: refers to the number of people who have been treated with metformin for 12 weeks or 24 weeks / total number of people. Continuous different dosage treatment rate: includes the continuous treatment rate of metformin at 1500mg/day and 2000mg/day doses, referring to the number of people who have been treated with metformin at 1500mg/day or 2000mg for 12 weeks or 24 weeks / total number of people. Discontinuation rate: refers to the number of people who discontinued metformin treatment at 12 weeks or 24 weeks during follow-up / total number of people.

    Time frame: 12 weeks, 24 weeks

07

Study locations

1 of 1 sites recruiting
  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences
    Beijing, Beijing 100037, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 21 months is below that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2025
First posted
Apr 17, 2025
StartActual
Mar 4, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06932874
Responsible party
Kefei Dou, MD (Professor, China National Center for Cardiovascular Diseases) — Principal investigator
First posted
Apr 17, 2025
Start date
Mar 4, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 30, 2025

Study contacts

Xiaojue Li MD, PhD
Contact
lixiaojue@fuwai.com
+86-10-18610154960

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion